Key points for me:
Covalent bonding of the antigen. We are the only next generation platform with covalent bonding. Significant
The platform was developed at U-Penn by the inventors of Car-t. We have the exclusive license and access to the best minds in the space, including Oxford and the spy tag tech.
Ambitious clinical program to develop and prove the tech will put us in a leadership position in next gen Car-T and many value opportunities.
We have some secret technology under development in cell therapy (Carina) which they keep hinting at but can’t talk about. I think this has the potential to enhance the efficacy of Car-t in solid tumors.
Overall this looks super positive in all directions. I think I’ll double down and hang on for five years.
GLTAH’s
- Forums
- ASX - By Stock
- Ann: PTX announces 3 next-gen CAR-T programs with OmniCAR
Key points for me:Covalent bonding of the antigen. We are the...
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
|
|||||
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $37.85M |
Open | High | Low | Value | Volume |
4.9¢ | 5.0¢ | 4.6¢ | $54.50K | 1.134M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 108715 | 4.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 189091 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 108715 | 0.047 |
3 | 249374 | 0.046 |
3 | 220000 | 0.045 |
2 | 106598 | 0.043 |
4 | 352851 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 189091 | 2 |
0.050 | 348310 | 3 |
0.052 | 19230 | 1 |
0.054 | 51093 | 1 |
0.055 | 325000 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
PTX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online